TEN-YEAR SAFETY AND EFFICACY ANALYSES OF THE BIG 02-98 PHASE III TRIAL WITH AN EXPLORATORY ANALYSIS ON THE ROLE OF KI67 IN PREDICTING BENEFIT OF ADJUVANT DOCETAXEL IN ER POSITIVE PATIENTS